HF
CNTX icon

HRT Financial’s Context Therapeutics CNTX Stock Holding History

HRT Financial’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-104,973
Closed -$275K – 4357
2026
Q1 		$275K Buy
+104,973
New +$245K ﹤0.01% 2940
2022
Q1 		– Sell
-10,160
Closed -$27K – 3205
2021
Q4 		$27K Buy
+10,160
New +$50.6K ﹤0.01% 2916

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

HRT Financial's CNTX Position: Q2 2026 in Review

HRT Financial sold out of Context Therapeutics (CNTX) in Q2 2026, closing a stake of 104,973 shares — an estimated $275K sold.

HRT Financial first reported a position in CNTX in Q4 2021 and held it in 2 quarters. The position peaked at $275K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • HRT Financial reported no remaining Context Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 104,973 Context Therapeutics shares in Q2 2026, an estimated $275K.
  • HRT Financial first reported a position in Context Therapeutics in Q4 2021 and held it in 2 quarters.
  • HRT Financial's Context Therapeutics position peaked at $275K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.